Exact Sciences Corporation, a leading provider of cancer screening and diagnostic tests, announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott at the special meeting of stockholders held earlier today.
At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Sciences common stock as of the January 9, 2026 record date for the special meeting, were voted in favor of the transaction. Final voting results from the special meeting will be reported by Exact Sciences in a Current Report on Form 8‑K filed with the U.S. Securities and Exchange Commission (the “SEC”).
Also Read: Kontakt.io Launches AI to Transform Care Delivery
Subject to the satisfaction or waiver of the remaining conditions to closing, the transaction is expected to close before the end of the second calendar quarter of 2026. Under the terms of the definitive agreement with Abbott, upon completion of the transaction, Exact Sciences’ stockholders will be entitled to receive $105.00 in cash, without interest and subject to any applicable withholding taxes, for each share of Exact Sciences common stock they owned as of immediately before the completion of the transaction.
Source: Businesswire
